Literature DB >> 24507984

Differential prognostic significance of extralobar and intralobar nodal metastases in patients with surgically resected stage II non-small cell lung cancer.

John C Haney1, Jennifer M Hanna1, Mark F Berry1, David H Harpole1, Thomas A D'Amico1, Betty C Tong1, Mark W Onaitis2.   

Abstract

OBJECTIVES: We sought to determine the prognostic significance of extralobar nodal metastases versus intralobar nodal metastases in patients with lung cancer and pathologic stage N1 disease.
METHODS: A retrospective review of a prospectively maintained lung resection database identified 230 patients with pathologic stage II, N1 non-small cell lung cancer from 1997 to 2011. The surgical pathology reports were reviewed to identify the involved N1 stations. The outcome variables included recurrence and death. Univariate and multivariate analyses were performed using the R statistical software package.
RESULTS: A total of 122 patients had extralobar nodal metastases (level 10 or 11); 108 patients were identified with intralobar nodal disease (levels 12-14). The median follow-up was 111 months. The baseline characteristics were similar in both groups. No significant differences were noted in the surgical approach, anatomic resections performed, or adjuvant therapy rates between the 2 groups. Overall, 80 patients developed recurrence during follow-up: 33 (30%) of 108 in the intralobar and 47 (38%) of 122 in the extralobar cohort. The median overall survival was 46.9 months for the intralobar cohort and 24.4 months for the extralobar cohort (P < .001). In a multivariate Cox proportional hazard model that included the presence of extralobar nodal disease, age, tumor size, tumor histologic type, and number of positive lymph nodes, extralobar nodal disease independently predicted both recurrence-free and overall survival (hazard ratio, 1.96; 95% confidence interval, 1.36-2.81; P = .001).
CONCLUSIONS: In patients who underwent surgical resection for stage II non-small cell lung cancer, the presence of extralobar nodal metastases at level 10 or 11 predicted significantly poorer outcomes than did nodal metastases at stations 12 to 14. This finding has prognostic importance and implications for adjuvant therapy and surveillance strategies for patients within the heterogeneous stage II (N1) category.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24507984      PMCID: PMC4336169          DOI: 10.1016/j.jtcvs.2013.12.015

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  17 in total

1.  Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC).

Authors:  F Tanaka; K Yanagihara; Y Otake; T Yamada; T Shoji; R Miyahara; K Inui; H Wada
Journal:  Eur J Cardiothorac Surg       Date:  2001-05       Impact factor: 4.191

2.  Survival and characteristics of lymph node involvement in patients with N1 non-small cell lung cancer.

Authors:  Toshihiro Osaki; Akira Nagashima; Takashi Yoshimatsu; Yuko Tashima; Kosei Yasumoto
Journal:  Lung Cancer       Date:  2004-02       Impact factor: 5.705

3.  Adjuvant chemotherapy for non-small cell lung cancer: practice patterns and outcomes in the general population of Ontario, Canada.

Authors:  Christopher M Booth; Frances A Shepherd; Yingwei Peng; Gail Darling; Gavin Li; Weidong Kong; William J Mackillop
Journal:  J Thorac Oncol       Date:  2012-03       Impact factor: 15.609

4.  Prognostic significance of surgical-pathologic N1 disease in non-small cell carcinoma of the lung.

Authors:  M Riquet; D Manac'h; F Le Pimpec-Barthes; A Dujon; A Chehab
Journal:  Ann Thorac Surg       Date:  1999-06       Impact factor: 4.330

5.  Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma of the lung. Significance of N1 level: lobar or hilar nodes.

Authors:  T Yano; H Yokoyama; T Inoue; H Asoh; K Tayama; Y Ichinose
Journal:  J Thorac Cardiovasc Surg       Date:  1994-06       Impact factor: 5.209

6.  Surgical treatment of clinical N1 non-small cell lung cancer: ongoing controversy over diagnosis and prognosis.

Authors:  Kei Miyoshi; Takeshi Mimura; Koichiro Iwanaga; Shuji Adachi; Noriaki Tsubota; Morihito Okada
Journal:  Surg Today       Date:  2010-04-28       Impact factor: 2.549

7.  Non-small cell lung cancer, version 2.2013.

Authors:  David S Ettinger; Wallace Akerley; Hossein Borghaei; Andrew C Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Ramaswamy Govindan; Frederic W Grannis; Stefan C Grant; Leora Horn; Thierry M Jahan; Ritsuko Komaki; Feng-Ming Spring Kong; Mark G Kris; Lee M Krug; Rudy P Lackner; Inga T Lennes; Billy W Loo; Renato Martins; Gregory A Otterson; Jyoti D Patel; Mary C Pinder-Schenck; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; Theresa A Shapiro; Scott J Swanson; Kurt Tauer; Douglas E Wood; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2013-06-01       Impact factor: 11.908

8.  The number of lymph node metastases as a prognostic factor in patients with N1 non-small cell lung cancer.

Authors:  Sirisha Jonnalagadda; Cardinale Smith; Grace Mhango; Juan P Wisnivesky
Journal:  Chest       Date:  2011-02-03       Impact factor: 9.410

9.  Prognostic variability among nonsmall cell lung cancer patients with pathologic N1 lymph node involvement. Epidemiological figures with strong clinical implications.

Authors:  Adele Caldarella; Emanuele Crocetti; Camilla E Comin; Alberto Janni; Andrea Lopes Pegna; Eugenio Paci
Journal:  Cancer       Date:  2006-08-15       Impact factor: 6.860

10.  Prognostic significance of surgical-pathologic N1 lymph node involvement in non-small cell lung cancer.

Authors:  Adalet Demir; Akif Turna; Celalettin Kocaturk; Mehmet Zeki Gunluoglu; Umit Aydogmus; Nur Urer; Mehmet Ali Bedirhan; Atilla Gurses; Seyit Ibrahim Dincer
Journal:  Ann Thorac Surg       Date:  2009-04       Impact factor: 4.330

View more
  4 in total

1.  Prognostic Factors of Pathological N1 Non-small Cell Lung Cancer After Curative Resection Without Adjuvant Chemotherapy.

Authors:  Youngkyu Moon; Sook Whan Sung; Jae Kil Park; Kyo Young Lee; Seha Ahn
Journal:  World J Surg       Date:  2019-04       Impact factor: 3.352

2.  Prognostic value of different N1 lymph node zones in pN1M0 non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Fengling Hu; Chutong Lin; Hongling Chu; Peng Ren; Jingdi Wang; Shaohua Ma
Journal:  Sci Rep       Date:  2021-11-03       Impact factor: 4.379

3.  Adjuvant chemotherapy may improve outcome of patients with non-small-cell lung cancer with metastasis of intrapulmonary lymph nodes after systematic dissection of N1 nodes.

Authors:  Xing Wang; Shi Yan; Yaqi Wang; Xiang Li; Chao Lyu; Yuzhao Wang; Jia Wang; Shaolei Li; Lijian Zhang; Yue Yang; Nan Wu
Journal:  Chin J Cancer Res       Date:  2018-12       Impact factor: 5.087

4.  Clinical analysis of sixty-four patients with T1aN2M0 stage non-small cell lung cancer who had undergone resection.

Authors:  Jian Xiong; Rui Wang; Yihua Sun; Haiquan Chen
Journal:  Thorac Cancer       Date:  2015-10-06       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.